Evidence map›Paper›PMID 28819997›Full record

ArticleClinical trials (London, England)2017

Comparisons of cancer staging systems should be based on overall performance in the population.

Kathleen F Kerr, Michael LeBlanc, Holly Janes

Abstract readLetterComment
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical trials (London, England), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Kathleen F Kerr1 Department of Biostatistics, University of Washington, Seattle, WA, USA.
Michael LeBlanc2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
Holly Janes2 Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

Funding

SWOG Statistics & Data Management Center complex - extension supplement for GY06U10CA180819 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Catherine M. Tangen · 2014 to 2026
$115.2M
Novel Biomarkers in Cardiac Surgery to Detect Acute Kidney InjuryR01HL085757 · NHLBI · YALE UNIVERSITY · PI PARIKH, CHIRAG R · 2007 to 2019
$10.3M
Use of Biomarkers in Diagnosis, Prognosis, Risk Prediction and Early Detection ofP01CA053996 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PRENTICE, ROSS L · 1991 to 2015
$9.4M
Statistical Methods for Evaluating Markers for Treatment SelectionR01CA152089 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI JANES, HOLLY · 2010 to 2021
$3.8M
NCI NIH HHS P01 CA053996NCI NIH HHS R01 CA152089NCI NIH HHS U10 CA180819NHLBI NIH HHS R01 HL085757
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsNeoplasm StagingHumansPrognosis

Identifiers

PMID28819997
PMCPMC5714691

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.